In collaboration with researchers at the University of Massachusetts Amherst, VivoSense published a new review paper in the Journal of Alzheimer’s Disease. The review summarizes how measures of real-world physical behavior, captured with digital health technologies, can contribute to more holistic assessment of functional independence in Alzheimer’s disease clinical research.
Read More
DATAcc announced the release of the Analytical Validation Library on May 23, 2023! Kate Lyden, Ph.D. and VivoSense CSO collaborated with other industry leaders to show ‘what good looks like’ regarding high-quality analytical validation. As new DHTs come online, industry-wide standards must be developed in tandem to ensure their ability to measure, detect or predict a clinical state.
Read More
In September 2022, a broad range of stakeholders representing regulators, Pharma and Biotech firms, technology service providers, innovators, and patients gathered in Zürich. This meeting, the second in a series hosted by the Swiss Federal Institute of Technology and the Foundation for the National Institutes of Health Biomarkers Consortium, sought to explore the role patient centricity must play in the development and validation of digital tools for gathering evidence. Director of Science Ieuan Clay, a member of the Biomarkers Consortium, represented VivoSense in the discussion examining four case studies of interest:
Read More
